Alnylam Launches ONPATTROŽ (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada

Tuesday, July 23, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

______________________________________________

1 Adams et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 379:11-21, July 5, 2018.

2 Patisiran Product Monograph, Alnylam Pharmaceuticals Inc, June 7, 2019.

3 Patisiran Product Monograph, Alnylam Pharmaceuticals Inc, June 7, 2019.

4 Adams et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 379:11-21, July 5, 2018.

5 Patisiran Product Monograph, Alnylam Pharmaceuticals Inc, June 7, 2019.

6 Adams et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 379:11-21, July 5, 2018.

7 Patisiran Product Monograph, Alnylam Pharmaceuticals Inc, June 7, 2019.

8 Health Canada https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/prfs_tpfd-eng.pdf Accessed June 17, 2019.

9 The American Journal of Managed Care https://www.ncbi.nlm.nih.gov/pubmed/28978215/ Accessed June 17, 2019.

10 Adams et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 379:11-21, July 5, 2018.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store